Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.84 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.84 |
| ▸ | NPC1 | O15118 | 2/20 | 0.65 |
| ▸ | RAB9A | P51151 | 2/20 | 0.65 |
| ▸ | KDM1A | O60341 | 1/20 | 0.60 |
| ▸ | MAOB | P27338 | 1/20 | 0.60 |
| ▸ | HTR2B | P41595 | 1/20 | 0.60 |
| ▸ | KIT | P10721 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 2/20 | 0.58 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.58 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | PLAU | P00749 | 2/20 | 0.56 |
| ▸ | PARP1 | P09874 | 1/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.56 |
| ▸ | MITF | O75030 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28031074 | 0.87 | PLAU (0.69) | MEN1KMT2ANPC1RAB9APOLB | |
| SCHEMBL7241176 | 0.86 | NPC1 (0.71) | MEN1KMT2ANPC1RAB9AMAOB | |
| SCHEMBL9746979 | 0.85 | PTGS1 (0.64) | MEN1KMT2APOLBTP53TDP1 | |
| SCHEMBL3069463 | 0.85 | PLAU (0.76) | MEN1KMT2ANPC1RAB9AKDM1A | |
| SCHEMBL30739642 | 0.85 | KMT2A (0.86) | MEN1KMT2ANPC1RAB9APOLB | |
| SCHEMBL1352493 | 0.84 | MEN1 (0.78) | MEN1KMT2ANPC1RAB9AKDM1A | |
| SCHEMBL7234929 | 0.84 | MEN1 (0.58) | MEN1KMT2ANPC1RAB9ATP53 | |
| SCHEMBL7244321 | 0.84 | PLAU (0.61) | MEN1KMT2ANPC1RAB9ATP53 | |
| SCHEMBL7242720 | 0.84 | TP53 (0.84) | MEN1KMT2ANPC1RAB9ATP53 | |
| SCHEMBL28595821 | 0.84 | KMT2A (0.84) | MEN1KMT2ANPC1RAB9APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030004162-A1 | Use of glycogen phosphorylase inhibitors | TREADWAY JUDITH L (US) | 2003-01-02 | — | — | US | disclosed |
| US-20020031816-A1 | METHOD OF INHIBITION OF HUMAN GLYCOGEN PHOSPHORYLASE | PFIZER PRODUCTS INC. | 2002-03-14 | — | — | US | disclosed |
| EP-1136071-A2 | Use of glycogen phosphorylase inhibitors | Pfizer Products Inc. (US) | 2001-09-26 | — | — | EP | disclosed |
| EP-0978279-A1 | Inhibitors of human glycogen phosphorylase | Pfizer Products Inc. (US) | 2000-02-09 | — | — | EP | disclosed |
| US-5998463-A | Glycogen phosphorylase inhibitors | PFIZER INC (US) | 1999-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004162-A1 | Use of glycogen phosphorylase inhibitors | PYGL, PYGM, GYS2 | MEN1 4180/4885KMT2A 2831/4885NPC1 2526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.